HC Wainwright Lifts Earnings Estimates for Coya Therapeutics

Coya Therapeutics, Inc. (NASDAQ:COYA) – Investment analysts at HC Wainwright lifted their FY2025 earnings per share estimates for Coya Therapeutics in a research note issued to investors on Monday, November 24th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.99) per share for the year, up from their previous forecast of ($1.30). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Coya Therapeutics’ current full-year earnings is ($1.15) per share. HC Wainwright also issued estimates for Coya Therapeutics’ Q4 2025 earnings at ($0.08) EPS, Q1 2026 earnings at ($0.37) EPS, Q2 2026 earnings at ($0.42) EPS, Q3 2026 earnings at ($0.47) EPS and FY2026 earnings at ($1.76) EPS.

Coya Therapeutics (NASDAQ:COYA) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.12). The business had revenue of $3.56 million during the quarter, compared to analysts’ expectations of $3.70 million. Coya Therapeutics had a negative net margin of 462.24% and a negative return on equity of 55.76%.

Several other equities research analysts have also recently weighed in on COYA. Weiss Ratings restated a “sell (d-)” rating on shares of Coya Therapeutics in a report on Wednesday, October 8th. D. Boral Capital reissued a “buy” rating and set a $15.00 price objective on shares of Coya Therapeutics in a research note on Wednesday, November 12th. Lake Street Capital reaffirmed a “buy” rating and issued a $17.00 target price on shares of Coya Therapeutics in a research note on Wednesday, November 5th. Chardan Capital reissued a “buy” rating and set a $14.00 price target on shares of Coya Therapeutics in a research report on Friday, November 14th. Finally, Wall Street Zen raised shares of Coya Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $16.00.

Coya Therapeutics Stock Up 5.3%

NASDAQ COYA opened at $6.38 on Wednesday. The company has a 50-day simple moving average of $6.09 and a two-hundred day simple moving average of $6.03. Coya Therapeutics has a 12-month low of $4.65 and a 12-month high of $8.29. The firm has a market cap of $133.47 million, a price-to-earnings ratio of -5.75 and a beta of 0.20.

Institutional Trading of Coya Therapeutics

A number of hedge funds have recently made changes to their positions in COYA. CM Management LLC increased its position in Coya Therapeutics by 50.0% during the 3rd quarter. CM Management LLC now owns 300,000 shares of the company’s stock valued at $1,710,000 after buying an additional 100,000 shares in the last quarter. Dauntless Investment Group LLC purchased a new stake in shares of Coya Therapeutics in the first quarter worth $1,083,000. Citadel Advisors LLC increased its holdings in shares of Coya Therapeutics by 51.3% during the third quarter. Citadel Advisors LLC now owns 65,240 shares of the company’s stock valued at $372,000 after acquiring an additional 22,120 shares in the last quarter. Jane Street Group LLC raised its position in shares of Coya Therapeutics by 101.7% in the 1st quarter. Jane Street Group LLC now owns 26,137 shares of the company’s stock worth $169,000 after purchasing an additional 13,176 shares during the last quarter. Finally, Prosperity Wealth Management Inc. boosted its stake in Coya Therapeutics by 16.4% in the 3rd quarter. Prosperity Wealth Management Inc. now owns 23,800 shares of the company’s stock worth $136,000 after purchasing an additional 3,350 shares in the last quarter. 39.75% of the stock is owned by institutional investors.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.